COMPOSITIONS AND METHODS FOR IMPROVING OR PRESERVING BRAIN FUNCTION

• US 20070179197A1
• Filed: 12/14/2006
• Published: 08/02/2007
• Est. Priority Date: 05/01/2000
• Status: Abandoned Application

• Current Assignee: Accela Incorporated (Piksel Incorporated)
• Original Assignee: Accela Incorporated (Piksel Incorporated)
• Inventors: Henderson, Samuel
• Application Number:
  US11/611,114
• Publication Number:
  US 20070179197A1
• Time in Patent Office: Days
• US Class Current: 514/547
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Inpairment (AAMI) or a dementing illness such as Alzheimer'"'"'s disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and/or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals.

Claims

1. A composition comprising medium chain triglycerides (MCT), in an amount effective for improving performance in, or reversing, preventing, reducing, or delaying decline in one or more of cognitive function, memory, motor performance, cerebrovascular function, or behavior in an aging mammal, wherein said composition increases a circulating concentration of at least one type of ketone body in the mammal;

and wherein the MCT are of the formula;

wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbons;

wherein the aging mammal has reached at least about 50% of its life expectancy.

2. The composition of claim 1 wherein greater than about 95% of the R1, R2, and R3 are 8 carbons in length.

3. The composition of claim 2 wherein the remaining R1, R2, and R3 are 6-carbon or 10-carbon fatty acids.

4. The composition of claim 1, which is a food composition, further comprising on a dry weight basis about 5-50% protein, 5-40% fat, 5-40% carbohydrate, and having a moisture content of 5-20%.

5. The composition of claim 1, comprising at least about 1% to about 50% MCT on a dry weight basis.

6. The composition of claim 1, wherein the mammal is a human.

7. The composition of claim 6, wherein the human has a characteristic associated with an age-related cognitive impairment selected from the group of Age-Associated Memory Impairment, Mild Cognitive Impairment and Alzheimer'"'"'s disease and related dementia.

8. The composition of claim 7 wherein the characteristic includes one or more of decreased ability to recall, short-term memory loss, decreased learning rate, decreased capacity for learning, decreased problem solving skills, decreased attention span, decreased motor performance, increased confusion, or dementia, as compared to a control mammal not having the characteristic.

9. A method for improving performance in, or reversing, preventing, reducing, or delaying decline in at least one of cognitive function memory, motor function, cerebrovascular function, or behavior in an aging mammal comprising the steps of:

identifying an aging mammal having, or at risk of, decline in at least one of cognitive function memory, motor function, cerebrovascular function, or behavior; and

administering to the mammal on an extended regular basis a composition comprising medium chain triglycerides (MCT) in an amount effective to improve performance in, or to reverse, prevent, reduce, or delay decline in at least one of cognitive function memory, motor function, cerebrovascular function, or behavior in the mammal wherein said composition increases the circulating concentration of at least one type of ketone body in the mammal; and

wherein the MCT are of the formula;

wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbons.

10. The method of claim 9 wherein greater than 95% of the R1, R2, and R3 are 8 carbons in length.

11. The method of claim 10 wherein the remaining R1, R2, and R3 are 6-carbon or 10-carbon fatty acids.

12. The method of claim 11 further comprising the step of monitoring the ketone body concentrations in the mammal.

13. The method of claim 9 wherein the amount of at least one of β

-hydroxybutyrate, acetoacetate and acetone is raised in the blood of the mammal.

14. The method of claim 9 wherein the composition comprises MCT in an amount effective for lowering the amount in the blood of the mammal of one or more of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, or VLDL.

15. The method of claim 14 wherein the amount of each of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, and VLDL is lowered in blood of the mammal.

16. The method of claim 9 wherein the composition comprises MCT in an amount effective for raising an amount in the blood of the mammal of one or more of glutamine, phenylalanine, HDL, or citrate.

17. The method of claim 16 wherein the amount of each of glutamine, phenylalanine, HDL, and citrate is raised in the blood of the mammal.

18. The method of claim 17 wherein the composition comprises MCT in an amount effective for lowering the amount of each of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, and VLDL.

19. The method of claim 9 wherein the composition comprises MCT in an amount effective for improving blood flow to the brain.

20. The method of claim 9 wherein the composition comprises MCT in an amount effective for improving the integrity of the blood brain barrier.

21. The method of claim 9, wherein the composition is a ready-to-drink beverage, powdered beverage formulation, nutritional or dietary supplement selected from the group consisting of gelatin capsule or tablet, suspension, parenteral solution, or a food product formulated for human consumption.

22. The method of claim 9, wherein the mammal is a human.

23. The method of claim 9, wherein the composition comprises at least about 1% to about 50% MCT on a dry weight basis.

24. The method of claim 9, wherein the administering step is on a regular basis comprising at least once daily.

25. The method of claim 24, wherein the composition is administered as part of a daily treatment regimen for at least about one week.

26. The method of claim 25, wherein the composition is administered as part of a daily treatment regimen for at least about three months.

27. The method of claim 9 wherein the composition comprises MCT in an amount effective for lowering blood urea nitrogen or decreasing protein degradation.

28. The method of claim 9 wherein the composition comprises MCT in an amount effective for lowering the amount or activity of alanine aminotransferase.

29. The method of claim 9 wherein the composition comprises MCT in an amount effective for lowering blood urea nitrogen or decreasing protein degradation.

30. A method for improving performance in, or reversing, preventing, reducing, or delaying decline in at least one of cognitive function, memory, motor function, cerebrovascular function, or behavior in an aging mammal comprising the steps of:

(a) identifying an aging mammal not having an age-related cognitive impairment disease; and

(b) administering to the mammal, on an extended regular basis, a composition comprising medium chain triglycerides (MCT) in an amount effective to improve performance in, or reverse, prevent, reduce, or delay decline in at least one of cognitive function, memory, motor function, cerebrovascular function, or behavior in the mammal;

wherein said composition increases the circulating concentration of at least one type of ketone body in the mammal; and

wherein the MCT are of the formula;

wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbons;

(c) measuring the concentration of at least one type of ketone body, and at least one of cognitive function, memory, motor function, cerebrovascular function, or behavior in the mammal at least periodically for the duration of the administering step;

(d) comparing at least one type of ketone body concentration and the measure of cognitive function, memory, motor function, cerebrovascular function, or behavior to that of a control mammal not receiving the administered composition;

(e) correlating the ketone body concentration with the measure of cognitive function, memory, motor function, cerebrovascular function, or behavior thereby establishing the improvement in performance of, or reversal, prevention, reduction, or delay of the decline of at least one of cognitive function, motor function, cerebrovascular function, or behavior as a result of the administration of the composition.

31. The method of claim 30, wherein greater than 95% of the R1, R2, and R3 are 8 carbons in length.

32. The method of claim 30, wherein the remaining R1, R2, and R3 are 6-carbon or 10-carbon fatty acids.

33. The method of claim 30, wherein the amount of at least one of β

-hydroxybutyrate, acetoacetate or acetone is raised in the blood of the mammal.

34. The method of claim 30, wherein the composition comprises MCT in an amount effective for lowering, in the blood of the mammal, an amount of one or more of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, or VLDL.

35. The method of claim 34, wherein the amount of each of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, and VLDL is lowered.

36. The method of claim 30, wherein the composition comprises MCT in an amount effective for raising an amount in the blood of the mammal of one or more of glutamine, phenylalanine, HDL, or citrate.

37. The method of claim 36, wherein the amount of each of glutamine, phenylalanine, HDL, and citrate is raised.

38. The method of claim 30, wherein the composition comprises MCT in an amount effective for lowering the amount of each of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, and VLDL.

39. The method of claim 30, wherein the composition comprises MCT in an amount effective for improving blood flow to the brain over time, or relative to the control mammal.

40. The method of claim 30, wherein the composition comprises MCT in an amount effective for improving the integrity of the blood brain barrier over time, or relative to the control mammal.

41. The method of claim 30, wherein the composition is a ready-to-drink beverage, powdered beverage formulation, nutritional or dietary supplement selected from the group consisting of gelatin capsule or table, suspension, parenteral solution, or a food product formulated for human consumption.

42. The method of claim 30, wherein the mammal is a human.

43. The method of claim 30, wherein the composition comprises at least about 1% to about 50% MCT on a dry weight basis.

44. The method of claim 30, wherein the administering step is on a regular basis comprising at least once daily.

45. The method of claim 44, wherein the composition is administered as part of a daily treatment regimen, for at least about one week to one year.

46. The method of claim 30 wherein the composition comprises MCT in an amount effective for lowering blood urea nitrogen or decreasing protein degradation.

47. The method of claim 30 wherein the composition comprises MCT in an amount effective for lowering the amount or activity of alanine aminotransferase.

48. The method of claim 30 wherein the composition comprises MCT in an amount effective for improving social behaviors.

49. A method for improving performance in, or reversing, preventing, reducing, or delaying decline in at least one of cognitive function, memory, motor function, cerebrovascular function, or behavior in a population of healthy aging mammals comprising the steps of:

(a) identifying a population of healthy aging mammals not having age-related cognitive impairment;

(b) dividing the population into at least a control group and one or more test groups;

(c) formulating at least one delivery system for delivering a composition comprising medium chain triglycerides (MCT) in an amount effective for elevating and maintaining an elevated level of at least one type of ketone body in the blood of an individual mammal;

wherein the MCT are of the formula;

wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbons;

wherein, on an extended regular basis, each test group receives a formulation delivering a composition comprising MCT and the control group does not receive any composition comprising MCT;

(d) comparing at least one of cognitive function, memory, motor function, cerebrovascular function, or behavior in the control and test groups;

(e) determining which of the delivery systems for delivering the composition comprising MCT was effective in improving performance in, or reversing, preventing, reducing, delaying decline of at least one of cognitive function, memory, motor function, cerebrovascular function, or behavior; and

(f) administering a treatment-based delivery system determined in step (e) to a population of aging mammals, thereby improving performance in, or reversing, preventing, reducing, delaying decline in at least one of cognitive function, memory, motor function, cerebrovascular function, or behavior.

50. The method of claim 49 wherein the extended regular basis comprises at least daily for a period of at least about one week to about one year.

51. The method of claim 49 further comprising the step of monitoring the concentration of at least one type of ketone body in each mammal in the control and test groups.

52. The method of claim 49 wherein the amount of at least one of β

-hydroxybutyrate, acetoacetate or acetone is raised.

53. The method of claim 49 wherein the composition comprises MCT in an amount effective for lowering the blood level of one or more of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, or VLDL.

54. The method of claim 53 wherein the level of each of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, and VLDL is lowered.

55. The method of claim 49 wherein the composition comprises MCT in an amount effective for raising the blood level of one or more of glutamine, phenylalanine, HDL, or citrate.

56. The method of claim 55 wherein the level of each of glutamine, phenylalanine, HDL, and citrate is raised.

57. The method of claim 56 wherein the composition comprises MCT in an amount effective for lowering the level of each of alanine, branched-chain amino acids, total lipoproteins, unsaturated fatty acids, and VLDL.

58. The method of claim 49 wherein the composition comprises MCT in an amount effective for improving blood flow to the brain.

59. The method of claim 49 wherein the composition comprises MCT in an amount effective for improving the integrity of the blood brain barrier.

60. The method of claim 49, wherein the mammal is a human.

61. The method of claim 49, wherein the composition comprises at least about 1% to about 50% MCTs on a dry weight basis.

62. The method of claim 49 wherein the composition comprises MCT in an amount effective for lowering blood urea nitrogen or decreasing protein degradation.

63. The method of claim 49 wherein the composition comprises MCT in an amount effective for lowering the amount or activity of alanine aminotransferase.

64. The method of claim 49 wherein the composition comprises MCT in an amount effective for improving social behaviors.